Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Matinas BioPharma Holdings, Inc. (MTNB)
USD0.34
-0.01 (-2.60%)
US AMEX Healthcare Biotechnology
Address
1545 Route 206 South 7921
Bedminster, NJ, US
Bedminster, NJ, US
CEO
Jerome D. Jabbour
Website
matinasbiopharma.com
IPO
2014-07-21
CIK 1582554 ISIN US5768103039
Description
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.34
-0.01 (-2.60%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
153.9K
Beta
1.68
Float Shares
4.38M
Free Float %
78.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.34% | -3.00% | +28.04% | +4.90% | -49.59% | +9.25% | +1.43% | -97.43% | -98.30% | -97.67% | -99.02% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
0.34
DCF (Unlevered)
0.43
+26.4%
DCF (Levered)
0.48
+41.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2025-07 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-53.76
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+59.8% ★ Q1'26: +9.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-318.5% Q1'26: -439.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+12.5% Q1'26: +25.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.21× Q1'26: -0.15× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
149.7K
est: 171.0K (-12.5%)
|
119.8K
est: 160.0K (-25.2%)
|
89.8K
est: 116.0K (-22.5%)
|
158.3K
est: 1.12M (-85.8%)
|
33.0K
est: 354.1K (-90.7%)
|
3.19M
est: 2.77M (+15.1%)
|
1.10M
est: 1.10M (-0.2%)
|
—
est: 500.0K (-100.0%)
|
—
est: 63.92M (-100.0%)
|
93.32M
93.32M – 93.32M
+46.0% YoY
|
45.20M
45.20M – 45.20M
-51.6% YoY
|
120.09M
120.09M – 120.09M
+165.7% YoY
|
| EBITDA |
-16.40M
est: -102.6K (-15,886.2%)
|
-14.43M
est: -96.0K (-14,929.4%)
|
-18.59M
est: -69.6K (-26,623.4%)
|
-23.92M
est: -670.5K (-3,466.8%)
|
-24.46M
est: -212.4K (-11,411.2%)
|
-24.23M
est: -1.66M (-1,357.7%)
|
-22.83M
est: -658.8K (-3,364.6%)
|
-19.19M
est: -100.0K (-19,090.2%)
|
-6.50M
est: -12.78M (+49.1%)
|
-18.66M
-18.66M – -18.66M
-46.0% YoY
|
-9.04M
-9.04M – -9.04M
+51.6% YoY
|
-24.02M
-24.02M – -24.02M
-165.7% YoY
|
| EBIT |
-16.50M
est: -102.6K (-15,984.2%)
|
-14.65M
est: -96.0K (-15,156.8%)
|
-18.92M
est: -69.6K (-27,095.9%)
|
-24.21M
est: -670.5K (-3,510.0%)
|
-24.74M
est: -212.4K (-11,543.0%)
|
-24.59M
est: -1.66M (-1,379.1%)
|
-23.77M
est: -658.8K (-3,507.5%)
|
-20.16M
est: -100.0K (-20,062.2%)
|
-6.96M
est: -12.78M (+45.6%)
|
-18.66M
-18.66M – -18.66M
-46.0% YoY
|
-9.04M
-9.04M – -9.04M
+51.6% YoY
|
-24.02M
-24.02M – -24.02M
-165.7% YoY
|
| Net Income |
-15.49M
est: -90.02M (+82.8%)
|
-14.08M
est: -35.28M (+60.1%)
|
-17.37M
est: -30.41M (+42.9%)
|
-22.45M
est: -27.35M (+17.9%)
|
-23.28M
est: -28.38M (+18.0%)
|
-21.00M
est: -26.54M (+20.9%)
|
-22.94M
est: -26.76M (+14.3%)
|
-24.25M
est: -22.22M (-9.1%)
|
-10.35M
est: -8.21M (-26.0%)
|
-27.37M
-27.37M – -27.37M
-233.3% YoY
|
-13.69M
-13.69M – -13.69M
+50.0% YoY
|
60.22M
60.22M – 60.22M
+540.0% YoY
|
| SGA |
7.64M
est: 13.19M (-42.1%)
|
7.98M
est: 12.34M (-35.4%)
|
7.78M
est: 8.95M (-13.1%)
|
10.01M
est: 86.23M (-88.4%)
|
10.19M
est: 27.32M (-62.7%)
|
11.10M
est: 213.79M (-94.8%)
|
10.37M
est: 84.72M (-87.8%)
|
8.73M
est: 32.36M (-73.0%)
|
6.88M
est: 4.14B (-99.8%)
|
6.04B
6.04B – 6.04B
+46.0% YoY
|
2.93B
2.93B – 2.93B
-51.6% YoY
|
7.77B
7.77B – 7.77B
+165.7% YoY
|
| EPS |
-8.56
est: -18.50 (+53.7%)
|
-7.18
est: -7.25 (+1.0%)
|
-5.37
est: -6.25 (+14.1%)
|
-5.23
est: -5.62 (+7.0%)
|
-5.04
est: -5.83 (+13.6%)
|
-3.00
est: -5.46 (+45.0%)
|
-5.28
est: -5.50 (+4.0%)
|
-4.98
est: -4.06 (-22.7%)
|
-2.00
est: -1.50 (-33.3%)
|
-5.00
-5.00 – -5.00
-233.3% YoY
|
-2.50
-2.50 – -2.50
+50.0% YoY
|
11.00
11.00 – 11.00
+540.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.60M
OE per share TTM
-1.19
Owner's Yield
-161.59%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
651.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
12
Total invested
46.4K
Insider transactions (90d)
0
Beneficial owners (>5%)
9
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Jennifer Lorenzo | 15.92M | 25.40% | 521.2K | 15.40M | 521.2K | 11.00 | IN | Jennifer Lorenzo is a US Citizen | 2017-03-22 | ↗ |
| 2 | GJG Capital, LLC | 15.40M | 24.50% | — | 15.40M | — | 11.00 | OO | Delaware | 2017-03-22 | ↗ |
| 3 | GJG Life Sciences, LLC | 15.40M | 24.50% | — | 15.40M | — | 15.40M | OO | Delaware | 2017-03-22 | ↗ |
| 4 | Vivo Opportunity, LLC | 5.99M | 4.80% | 5.99M | — | 5.99M | — | OO | Delaware | 2019-03-26 | ↗ |
| 5 | Vivo Capital IX, LLC | 825.0K | 0.70% | 825.0K | — | 825.0K | — | OO | Delaware | 2019-03-26 | ↗ |
| 6 | Highbridge Capital Management, LLC | 595.6K | 9.99% | — | 595.6K | — | — | IA, OO | State of Delaware | 2024-10-25 | ↗ |
| 7 | Boxer Asset Management Inc. | — | 0.00% | — | — | — | — | CO | — | 2022-02-14 | ↗ |
| 8 | Boxer Capital, LLC | — | 0.00% | — | — | — | — | OO | — | 2022-02-14 | ↗ |
| 9 | Joe Lewis | — | 0.00% | — | — | — | — | IN | — | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
12
-17 vs prev Q
New positions
4
Closed positions
21
Increased
4
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 65.7K +65.7K (+100.0%) | 38.5K +38.5K (+100.0%) | 1.21% +1.209 pp | 0.00% +0.000 pp | USD0.59 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 59.7K +— (+0.0%) | 35.0K -77.9K (-69.0%) | 1.10% -0.075 pp | 0.00% +0.000 pp | USD3.54 -83.3% | 6 qtrs — |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 56.0K +— (+0.0%) | 32.8K -73.0K (-69.0%) | 1.03% -0.071 pp | 0.00% +0.000 pp | USD2.93 -79.9% | 6 qtrs — |
| 4 | BLACKROCK, INC. | 49.7K +— (+0.0%) | 29.1K -64.7K (-69.0%) | 0.91% -0.063 pp | 0.00% +0.000 pp | USD3.54 -83.3% | 6 qtrs — |
| 5 | DRW SECURITIES, LLC | 46.4K +46.4K (+100.0%) | 27.2K +27.2K (+100.0%) | 0.85% +0.853 pp | 0.00% +0.001 pp | USD0.59 +0.0% | 1 qtrs NEW |
| 6 | HOLOS INTEGRATED WEALTH LLC | 32.5K +— (+0.0%) | 20.1K -35.4K (-63.7%) | 0.60% -0.041 pp | 0.01% -0.021 pp | USD0.51 +15.7% | 5 qtrs — |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 29.0K +700.0 (+2.5%) | 17.0K -36.5K (-68.2%) | 0.53% -0.023 pp | 0.00% +0.000 pp | USD0.71 -16.9% | 5 qtrs — |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 21.1K +21.1K (+100.0%) | 12.4K +12.4K (+100.0%) | 0.39% +0.388 pp | 0.00% +0.000 pp | USD0.59 +0.0% | 1 qtrs NEW |
| 9 | XTX TOPCO LTD | 16.9K +16.9K (+100.0%) | 9.9K +9.9K (+100.0%) | 0.31% +0.311 pp | 0.00% +0.000 pp | USD0.59 +0.0% | 1 qtrs NEW |
| 10 | JANE STREET GROUP, LLC | 15.9K +15.9K (+100.0%) | 9.3K +9.3K (+100.0%) | 0.29% +0.293 pp | 0.00% +0.000 pp | USD0.59 +0.0% | 1 qtrs NEW |
| 11 | VIRTU FINANCIAL LLC | 15.6K +15.6K (+100.0%) | 9.0K +9.0K (+100.0%) | 0.29% +0.286 pp | 0.00% +0.000 pp | USD0.59 +0.0% | 1 qtrs NEW |
| 12 | STATE STREET CORP | 15.3K +— (+0.0%) | 9.0K -20.0K (-69.0%) | 0.28% -0.019 pp | 0.00% +0.000 pp | USD3.54 -83.3% | 6 qtrs — |
| 13 | SARGENT INVESTMENT GROUP, LLC | 12.7K -23.9K (-65.3%) | 7.5K -61.8K (-89.2%) | 0.23% -0.486 pp | 0.00% -0.009 pp | USD3.49 -83.1% | 6 qtrs — |
| 14 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.9K +1.4K (+97.9%) | 1.7K -1.1K (-38.6%) | 0.05% +0.024 pp | 0.00% +0.000 pp | USD0.71 -16.9% | 5 qtrs — |
| 15 | BANK OF AMERICA CORP /DE/ | 991.00 +12.0 (+1.2%) | 581.00 -1.3K (-68.6%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD3.48 -83.0% | 6 qtrs — |
| 16 | UBS GROUP AG | 607.00 +407.0 (+203.5%) | 356.00 -22.0 (-5.8%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD0.92 -35.9% | 6 qtrs — |
| 17 | MORGAN STANLEY | 561.00 +— (+0.0%) | 328.00 -732.0 (-69.1%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD2.31 -74.5% | 6 qtrs — |
| 18 | FARTHER FINANCE ADVISORS, LLC | 422.00 +— (+0.0%) | 247.00 -551.0 (-69.0%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD1.87 -68.4% | 4 qtrs — |
| 19 | COSTELLO ASSET MANAGEMENT, INC | 200.00 +— (+0.0%) | 117.00 -261.0 (-69.0%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD0.52 +13.5% | 4 qtrs — |
| 20 | WELLS FARGO & COMPANY/MN | 102.00 +— (+0.0%) | 60.00 -133.0 (-68.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.54 -83.3% | 6 qtrs — |
| 21 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 61.00 +— (+0.0%) | 36.00 -79.0 (-68.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.52 -83.2% | 6 qtrs — |
| 22 | EVERSOURCE WEALTH ADVISORS, LLC | 60.00 +— (+0.0%) | 35.00 -78.0 (-69.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.53 -83.3% | 6 qtrs — |
| 23 | JONES FINANCIAL COMPANIES LLLP | 60.00 +— (+0.0%) | 35.00 -79.0 (-69.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.88 -33.0% | 3 qtrs — |
| 24 | ADVISOR GROUP HOLDINGS, INC. | 50.00 -160.0 (-76.2%) | 28.00 -366.0 (-92.9%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD3.38 -82.5% | 6 qtrs — |
| 25 | VISION FINANCIAL MARKETS LLC | 40.00 +— (+0.0%) | 24.00 -52.0 (-68.4%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.50 +18.0% | 4 qtrs — |
| 26 | ROTHSCHILD INVESTMENT LLC | 14.00 +— (+0.0%) | 8.00 -18.0 (-69.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.50 -83.1% | 6 qtrs — |
| 27 | SAGEVIEW ADVISORY GROUP, LLC | 10.00 +10.0 (+100.0%) | 6.00 +6.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.50 +18.0% | 1 qtrs NEW |
| 28 | SBI SECURITIES CO., LTD. | 11.00 +— (+0.0%) | 6.00 -15.0 (-71.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.45 +31.1% | 5 qtrs — |
| 29 | MAI CAPITAL MANAGEMENT | 2.00 +— (+0.0%) | 2.00 -2.0 (-50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.50 +18.0% | 3 qtrs — |
| 30 | FMR LLC | — -5.0 (-100.0%) | — -9.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 31 | CITIGROUP INC | — -1.3K (-100.0%) | — -2.4K (-100.0%) | 0.00% -0.025 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 32 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | — -500.0 (-100.0%) | — -945.0 (-100.0%) | 0.00% -0.010 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 33 | TWO SIGMA SECURITIES, LLC | — -12.6K (-100.0%) | — -23.7K (-100.0%) | 0.00% -0.247 pp | 0.00% -0.004 pp | USD— | 4 qtrs SOLD |
| 34 | NORTHERN TRUST CORP | — -22.6K (-100.0%) | — -42.7K (-100.0%) | 0.00% -0.444 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 35 | HRT FINANCIAL LP | — -10.8K (-100.0%) | — -20.0K (-100.0%) | 0.00% -0.212 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 31.8K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
11
Sells
0
Shares acquired
5.88M
Shares disposed
—
Cash buys
6.00
Cash sales
—
Net activity
+5,875,869
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-30 | Smith Robin L | Director | A-Award | A | Stock Option (right to Buy) | 11,600 | 0.59 | 6.8K | 11,600 | D | ↗ |
| 2025-04-30 | NEUGEBOREN EDWARD | Director | A-Award | A | Stock Option (right to Buy) | 11,600 | 0.59 | 6.8K | 11,600 | D | ↗ |
| 2025-04-30 | Murphy Keith | Director | A-Award | A | Stock Option (right to Buy) | 11,600 | 0.59 | 6.8K | 11,600 | D | ↗ |
| 2025-04-30 | Jabbour Jerome D | Director / Officer | A-Award | A | Stock Option (right to Buy) | 70,100 | 0.59 | 41.4K | 70,100 | D | ↗ |
| 2025-04-30 | D An Evelyn | Director | A-Award | A | Stock Option (right to Buy) | 11,600 | 0.59 | 6.8K | 11,600 | D | ↗ |
| 2025-04-08 | Sanitam Partners LLC | 10% Owner | P-Purchase | A | Series C Convertible Preferred Stock | 703 | 0.59 | 411.96 | 1,406 | D | ↗ |
| 2025-04-08 | Pembroke & Partners LLC | 10% Owner | P-Purchase | A | Series C Convertible Preferred Stock | 492 | 0.59 | 288.31 | 984 | D | ↗ |
| 2025-04-08 | EIDE ROBERT J | 10% Owner | P-Purchase | A | Series C Convertible Preferred Stock | 492 | 0.59 | 288.31 | 984 | I | ↗ |
| 2025-03-11 | NEUGEBOREN EDWARD | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-11 | Murphy Keith | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-13 | Smith Robin L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-13 | Sanitam Partners LLC | 10% Owner | — | — | Warrants | 2,399,318 | 0.00 | — | 0 | D | ↗ |
| 2025-02-13 | STERN ADAM K | 10% Owner | — | — | Warrants | 4,798,636 | 0.00 | — | 0 | I | ↗ |
| 2025-02-13 | Pembroke & Partners LLC | 10% Owner | — | — | Warrants | 1,679,182 | 0.00 | — | 0 | D | ↗ |
| 2025-02-13 | EIDE ROBERT J | 10% Owner | — | — | Series C Convertible Preferred Stock | 839,591 | 0.00 | — | 0 | I | ↗ |
| 2025-02-05 | D An Evelyn | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-15 | Matkovits Theresa | Officer | A-Award | A | Stock Option (right to Buy) | 1,300,000 | 0.25 | 321.1K | 1,300,000 | — | ↗ |
| 2023-12-15 | Liu Hui | Officer | A-Award | A | Stock Option (right to Buy) | 1,000,000 | 0.25 | 247.0K | 1,000,000 | — | ↗ |
| 2023-12-15 | Kucinski Keith A | Officer | A-Award | A | Stock Option (right to Buy) | 1,000,000 | 0.25 | 247.0K | 1,000,000 | — | ↗ |
| 2023-12-15 | Jabbour Jerome D | Director / Officer | A-Award | A | Stock Option (right to Buy) | 3,500,000 | 0.25 | 864.5K | 3,500,000 | — | ↗ |
| 2023-12-15 | Hoover Thomas | Officer | A-Award | A | Stock Option (right to Buy) | 1,000,000 | 0.25 | 247.0K | 1,000,000 | — | ↗ |
| 2023-12-15 | Ferguson James J. III | Officer | A-Award | A | Stock Option (right to Buy) | 1,200,000 | 0.25 | 296.4K | 1,200,000 | — | ↗ |
| 2023-11-01 | WIKLER MATTHEW | Director | A-Award | A | Stock option (right to buy) | 437,244 | 0.21 | 91.3K | 437,244 | — | ↗ |
| 2023-11-01 | Scibetta James S | Director | A-Award | A | Stock option (right to buy) | 437,244 | 0.21 | 91.3K | 437,244 | — | ↗ |
| 2023-11-01 | Giordano Natasha | Director | A-Award | A | Stock option (right to buy) | 437,244 | 0.21 | 91.3K | 437,244 | — | ↗ |
| 2023-11-01 | Ende Eric J | Director | A-Award | A | Stock option (right to buy) | 437,244 | 0.21 | 91.3K | 437,244 | — | ↗ |
| 2023-11-01 | Corzo Kathryn Penkus | Director | A-Award | A | Stock option (right to buy) | 437,244 | 0.21 | 91.3K | 437,244 | — | ↗ |
| 2023-11-01 | CONRAD HERBERT J | Director | A-Award | A | Stock option (right to buy) | 437,244 | 0.21 | 91.3K | 437,244 | — | ↗ |
| 2022-12-20 | Matkovits Theresa | Officer | A-Award | A | Stock Option (right to Buy) | 625,000 | 0.00 | — | 625,000 | — | ↗ |
| 2022-12-20 | Liu Hui | Officer | A-Award | A | Stock Option (right to Buy) | 625,000 | 0.00 | — | 625,000 | — | ↗ |
| 2022-12-20 | Kucinski Keith A | Officer | A-Award | A | Stock Option (right to Buy) | 625,000 | 0.00 | — | 625,000 | — | ↗ |
| 2022-12-20 | Jabbour Jerome D | Officer | A-Award | A | Stock Option (right to Buy) | 1,988,300 | 0.00 | — | 1,988,300 | — | ↗ |
| 2022-12-20 | Hoover Thomas | Officer | A-Award | A | Stock Option (right to Buy) | 475,000 | 0.00 | — | 475,000 | — | ↗ |
| 2022-12-20 | Ferguson James J. III | Officer | A-Award | A | Stock Option (right to Buy) | 625,000 | 0.00 | — | 625,000 | — | ↗ |
| 2022-11-14 | WIKLER MATTHEW | Director | A-Award | A | Stock option (right to buy) | 142,657 | 0.00 | — | 142,657 | — | ↗ |
| 2022-11-14 | Scibetta James S | Director | A-Award | A | Stock option (right to buy) | 142,657 | 0.00 | — | 142,657 | — | ↗ |
| 2022-11-14 | Giordano Natasha | Director | A-Award | A | Stock option (right to buy) | 142,657 | 0.00 | — | 142,657 | — | ↗ |
| 2022-11-14 | Ende Eric J | Director | A-Award | A | Stock option (right to buy) | 142,657 | 0.00 | — | 142,657 | — | ↗ |
| 2022-11-14 | Corzo Kathryn Penkus | Director | A-Award | A | Stock option (right to buy) | 142,657 | 0.00 | — | 142,657 | — | ↗ |
| 2022-11-14 | CONRAD HERBERT J | Director | A-Award | A | Stock option (right to buy) | 142,657 | 0.00 | — | 142,657 | — | ↗ |
| 2022-06-22 | CONRAD HERBERT J | Director | G-Gift | A | Common Stock, par value $0.0001 per share | 1,358,122 | 0.00 | — | 4,694,566 | — | ↗ |
| 2021-12-31 | WIKLER MATTHEW | Director | A-Award | A | Common Stock | 7,859 | 0.00 | — | 290,472 | — | ↗ |
| 2021-12-14 | Matkovits Theresa | Officer | A-Award | A | Stock Option (right to Buy) | 500,000 | 0.92 | 460.0K | 500,000 | — | ↗ |
| 2021-12-14 | MANNINO RAPHAEL J | Officer | A-Award | A | Stock Option (right to Buy) | 275,000 | 0.92 | 253.0K | 275,000 | — | ↗ |
| 2021-12-14 | Kucinski Keith A | Officer | A-Award | A | Stock Option (right to Buy) | 500,000 | 0.92 | 460.0K | 500,000 | — | ↗ |
| 2021-12-14 | Jabbour Jerome D | Director / Officer | A-Award | A | Stock Option (right to Buy) | 1,658,100 | 0.92 | 1.53M | 1,658,100 | — | ↗ |
| 2021-12-14 | Hui Liu | Officer | A-Award | A | Stock Option (right to Buy) | 275,000 | 0.92 | 253.0K | 275,000 | — | ↗ |
| 2021-12-14 | Hoover Thomas | Officer | A-Award | A | Stock Option (right to Buy) | 850,000 | 0.92 | 782.0K | 850,000 | — | ↗ |
| 2021-12-14 | Ferguson James J. III | Officer | A-Award | A | Stock Option (right to Buy) | 587,600 | 0.92 | 540.6K | 587,600 | — | ↗ |
| 2021-12-06 | Hoover Thomas | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-01 | WIKLER MATTHEW | Director | A-Award | A | Stock option (right to buy) | 90,882 | 1.12 | 101.8K | 90,882 | — | ↗ |
| 2021-11-01 | Scibetta James S | Director | A-Award | A | Stock option (right to buy) | 90,882 | 1.12 | 101.8K | 90,882 | — | ↗ |
| 2021-11-01 | Giordano Natasha | Director | A-Award | A | Stock option (right to buy) | 90,882 | 1.12 | 101.8K | 90,882 | — | ↗ |
| 2021-11-01 | Ende Eric J | Director | A-Award | A | Stock option (right to buy) | 90,882 | 1.12 | 101.8K | 90,882 | — | ↗ |
| 2021-11-01 | Corzo Kathryn Penkus | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-01 | CONRAD HERBERT J | Director | A-Award | A | Stock option (right to buy) | 90,882 | 1.12 | 101.8K | 90,882 | — | ↗ |
| 2021-09-30 | WIKLER MATTHEW | Director | A-Award | A | Common Stock | 6,106 | 0.00 | — | 282,613 | — | ↗ |
| 2021-09-03 | MANNINO RAPHAEL J | Officer | J-Other | A | Common Stock, par value $0.0001 per share | 462,150 | 0.00 | — | 1,919,715 | — | ↗ |
| 2021-08-04 | CONRAD HERBERT J | Director | G-Gift | A | Common Stock, par value $0.0001 per share | 494,622 | 0.00 | — | 3,336,444 | — | ↗ |
| 2021-07-07 | CONRAD HERBERT J | Director | G-Gift | A | Common Stock, par value $0.0001 per share | 1,280,917 | 0.00 | — | 2,841,822 | — | ↗ |
| 2021-06-30 | WIKLER MATTHEW | Director | A-Award | A | Common Stock | 10,244 | 0.00 | — | 276,507 | — | ↗ |
| 2021-06-19 | WIKLER MATTHEW | Director | C-Conversion | D | Series B Preferred Stock | 6 | 0.50 | 3.00 | 0 | — | ↗ |
| 2021-06-19 | Scibetta James S | Director | C-Conversion | D | Series B Preferred Stock | 12 | 0.50 | 6.00 | 0 | — | ↗ |
| 2021-06-19 | MANNINO RAPHAEL J | Officer | C-Conversion | A | Common Stock, par value $0.0001 per share | 20,000 | 0.00 | — | 1,457,565 | — | ↗ |
| 2021-06-19 | Jabbour Jerome D | Director / Officer | C-Conversion | D | Series B Preferred Stock | 15 | 0.50 | 7.50 | 0 | — | ↗ |
| 2021-06-19 | Ende Eric J | Director | C-Conversion | D | Series B Preferred Stock | 12 | 0.50 | 6.00 | 0 | — | ↗ |
| 2021-06-19 | CONRAD HERBERT J | Director | C-Conversion | A | Common Stock, par value $0.0001 per share | 200,000 | 0.00 | — | 1,560,905 | — | ↗ |
| 2021-05-20 | CONRAD HERBERT J | Director | G-Gift | A | Common Stock, par value $0.0001 per share | 1,145,905 | 0.00 | — | 1,320,905 | — | ↗ |
| 2021-03-31 | WIKLER MATTHEW | Director | A-Award | A | Common Stock | 7,560 | 0.00 | — | 251,863 | — | ↗ |
| 2021-01-13 | CONRAD HERBERT J | Director | G-Gift | D | Series B Convertible Preferred Stock | 100 | 0.50 | 50.00 | 0 | — | ↗ |
| 2021-01-01 | Matkovits Theresa | Officer | A-Award | A | Stock option (right to buy) | 425,000 | 1.36 | 578.0K | 425,000 | — | ↗ |
| 2021-01-01 | MANNINO RAPHAEL J | Officer | A-Award | A | Stock option (right to buy) | 200,000 | 1.36 | 272.0K | 200,000 | — | ↗ |
| 2021-01-01 | Kucinski Keith A | Officer | A-Award | A | Stock option (right to buy) | 500,000 | 1.36 | 680.0K | 500,000 | — | ↗ |
| 2021-01-01 | Jabbour Jerome D | Director / Officer | A-Award | A | Stock option (right to buy) | 1,600,000 | 1.36 | 2.18M | 1,600,000 | — | ↗ |
| 2021-01-01 | Hui Liu | Officer | A-Award | A | Stock option (right to buy) | 250,000 | 1.36 | 340.0K | 250,000 | — | ↗ |
| 2021-01-01 | Ferguson James J. III | Officer | A-Award | A | Stock option (right to buy) | 575,000 | 1.36 | 782.0K | 575,000 | — | ↗ |
| 2020-12-31 | WIKLER MATTHEW | Director | A-Award | A | Common Stock | 11,673 | 0.00 | — | 244,303 | — | ↗ |
| 2020-12-01 | Hui Liu | Officer | A-Award | A | Stock option (right to buy) | 350,000 | 1.07 | 374.5K | 350,000 | — | ↗ |
| 2020-11-02 | WIKLER MATTHEW | Director | A-Award | A | Stock option (right to buy) | 122,605 | 0.82 | 100.5K | 122,605 | — | ↗ |
| 2020-11-02 | Scibetta James S | Director | A-Award | A | Stock option (right to buy) | 122,605 | 0.82 | 100.5K | 122,605 | — | ↗ |
| 2020-11-02 | LEPORE PATRICK G | Director | A-Award | A | Stock option (right to buy) | 122,605 | 0.82 | 100.5K | 122,605 | — | ↗ |
| 2020-11-02 | Ende Eric J | Director | A-Award | A | Stock option (right to buy) | 122,605 | 0.82 | 100.5K | 122,605 | — | ↗ |
| 2020-11-02 | CONRAD HERBERT J | Director | A-Award | A | Stock option (right to buy) | 122,605 | 0.82 | 100.5K | 122,605 | — | ↗ |
| 2020-09-30 | WIKLER MATTHEW | Director | A-Award | A | Common Stock | 20,725 | 0.00 | — | 232,630 | — | ↗ |
| 2020-09-14 | Giordano Natasha | Director | — | D | Option (right to buy) | 287,917 | 0.69 | 199.5K | 0 | — | ↗ |
| 2020-08-21 | STERN ADAM K | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 20,000 | 0.83 | 16.6K | 3,301,983 | — | ↗ |
| 2020-06-30 | WIKLER MATTHEW | Director | A-Award | A | Common Stock | 20,537 | 0.00 | — | 211,905 | — | ↗ |
| 2020-06-23 | WIKLER MATTHEW | Director | J-Other | A | Common Stock, par value $0.0001 per share | 1,800 | 0.00 | — | 191,368 | — | ↗ |
| 2020-06-23 | Scibetta James S | Director | J-Other | A | Common Stock, par value $0.0001 per share | 3,600 | 0.00 | — | 621,158 | — | ↗ |
| 2020-06-23 | STERN ADAM K | Director | J-Other | A | Common Stock, par value $0.0001 per share | 25,500 | 0.00 | — | 3,281,983 | — | ↗ |
| 2020-06-23 | MANNINO RAPHAEL J | Officer | J-Other | A | Common Stock, par value $0.0001 per share | 3,000 | 0.00 | — | 1,429,565 | — | ↗ |
| 2020-06-23 | Jabbour Jerome D | Director / Officer | J-Other | A | Common Stock, par value $0.0001 per share | 4,500 | 0.00 | — | 804,011 | — | ↗ |
| 2020-06-23 | Ende Eric J | Director | J-Other | A | Common Stock, par value $0.0001 per share | 3,600 | 0.00 | — | 115,292 | — | ↗ |
| 2020-06-23 | CONRAD HERBERT J | Director | J-Other | A | Common Stock, par value $0.0001 per share | 30,000 | 0.00 | — | 544,622 | — | ↗ |
| 2020-06-17 | Matkovits Theresa | Officer | A-Award | A | Stock option (right to buy) | 175,000 | 0.82 | 142.6K | 175,000 | — | ↗ |
| 2020-06-17 | MANNINO RAPHAEL J | Officer | A-Award | A | Stock option (right to buy) | 50,000 | 0.82 | 40.8K | 50,000 | — | ↗ |
| 2020-06-17 | Kucinski Keith A | Officer | A-Award | A | Stock option (right to buy) | 175,000 | 0.82 | 142.6K | 175,000 | — | ↗ |
| 2020-06-17 | Jabbour Jerome D | Director / Officer | A-Award | A | Stock option (right to buy) | 500,000 | 0.82 | 407.5K | 500,000 | — | ↗ |
| 2020-06-17 | Ferguson James J. III | Officer | A-Award | A | Stock option (right to buy) | 250,000 | 0.82 | 203.8K | 250,000 | — | ↗ |
| 2020-06-04 | CONRAD HERBERT J | Director | G-Gift | A | Common Stock, par value $0.0001 per share | 2,639,039 | 0.00 | — | 2,639,039 | — | ↗ |
| 2020-05-14 | LEPORE PATRICK G | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 100,000 | 0.73 | 73.1K | 400,000 | — | ↗ |
| 2020-05-13 | CONRAD HERBERT J | Director | G-Gift | A | Common Stock, par value $0.0001 per share | 2,639,039 | 0.00 | — | 2,764,039 | — | ↗ |
| 2020-04-03 | STERN ADAM K | Director | M-Exempt | A | Common Stock, par value $0.0001 per share | 278,407 | 0.50 | 139.2K | 1,337,399 | — | ↗ |
| 2020-03-31 | WIKLER MATTHEW | Director | A-Award | A | Common Stock | 26,450 | 0.00 | — | 189,568 | — | ↗ |
| 2020-03-17 | STERN ADAM K | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 10,000 | 0.65 | 6.5K | 10,000 | — | ↗ |
| 2020-03-17 | Jabbour Jerome D | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 10,000 | 0.65 | 6.5K | 799,511 | — | ↗ |
| 2020-01-01 | Matkovits Theresa | Officer | A-Award | A | Stock option (right to buy) | 350,000 | 2.27 | 794.5K | 350,000 | — | ↗ |
| 2020-01-01 | MANNINO RAPHAEL J | Officer | A-Award | A | Stock option (right to buy) | 100,000 | 2.27 | 227.0K | 100,000 | — | ↗ |
| 2020-01-01 | Kucinski Keith A | Officer | A-Award | A | Stock option (right to buy) | 350,000 | 2.27 | 794.5K | 350,000 | — | ↗ |
| 2020-01-01 | Jabbour Jerome D | Director / Officer | A-Award | A | Stock option (right to buy) | 1,000,000 | 2.27 | 2.27M | 1,000,000 | — | ↗ |
| 2020-01-01 | Ferguson James J. III | Officer | A-Award | A | Stock option (right to buy) | 500,000 | 2.27 | 1.14M | 500,000 | — | ↗ |
| 2019-12-31 | WIKLER MATTHEW | Director | A-Award | A | Common Stock, par value $0.0001 per share | 6,994 | 0.00 | — | 163,118 | — | ↗ |
| 2019-12-31 | Scibetta James S | Director | A-Award | A | Common Stock, par value $0.0001 per share | 8,260 | 0.00 | — | 617,558 | — | ↗ |
| 2019-12-31 | CONRAD HERBERT J | Director | A-Award | A | Common Stock, par value $0.0001 per share | 10,573 | 0.00 | — | 514,622 | — | ↗ |
| 2019-11-25 | Kucinski Keith A | Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 58,000 | 1.23 | 71.2K | 94,500 | — | ↗ |
| 2019-11-22 | Kucinski Keith A | Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 36,500 | 1.20 | 43.8K | 36,500 | — | ↗ |
| 2019-11-15 | LEPORE PATRICK G | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 100,000 | 1.06 | 105.5K | 300,000 | — | ↗ |
| 2019-11-01 | WIKLER MATTHEW | Director | A-Award | A | Stock option (right to buy) | 107,416 | 0.91 | 98.0K | 107,416 | — | ↗ |
| 2019-11-01 | Scibetta James S | Director | A-Award | A | Stock option (right to buy) | 107,416 | 0.91 | 98.0K | 107,416 | — | ↗ |
| 2019-11-01 | STERN ADAM K | Director | A-Award | A | Stock option (right to buy) | 107,416 | 0.91 | 98.0K | 107,416 | — | ↗ |
| 2019-11-01 | LEPORE PATRICK G | Director | A-Award | A | Stock option (right to buy) | 107,416 | 0.91 | 98.0K | 107,416 | — | ↗ |
| 2019-11-01 | Ende Eric J | Director | A-Award | A | Stock option (right to buy) | 107,416 | 0.91 | 98.0K | 107,416 | — | ↗ |
| 2019-11-01 | CONRAD HERBERT J | Director | A-Award | A | Stock option (right to buy) | 107,416 | 0.91 | 98.0K | 107,416 | — | ↗ |
| 2019-09-30 | WIKLER MATTHEW | Director | A-Award | A | Common Stock, par value $0.0001 per share | 25,179 | 0.00 | — | 154,924 | — | ↗ |
| 2019-09-30 | Scibetta James S | Director | A-Award | A | Common Stock, par value $0.0001 per share | 29,739 | 0.00 | — | 606,898 | — | ↗ |
| 2019-09-30 | CONRAD HERBERT J | Director | A-Award | A | Common Stock, par value $0.0001 per share | 38,066 | 0.00 | — | 504,049 | — | ↗ |
| 2019-08-20 | Ende Eric J | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 20,000 | 0.66 | 13.2K | 109,292 | — | ↗ |
| 2019-08-19 | STERN ADAM K | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 10,400 | 0.70 | 7.3K | 804,392 | — | ↗ |
| 2019-08-19 | Jabbour Jerome D | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 14,650 | 0.68 | 10.0K | 786,511 | — | ↗ |
| 2019-08-19 | Ende Eric J | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 20,000 | 0.68 | 13.7K | 89,292 | — | ↗ |
| 2019-08-16 | LEPORE PATRICK G | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 100,000 | 0.72 | 71.9K | 200,000 | — | ↗ |
| 2019-07-29 | STERN ADAM K | Director | C-Conversion | A | Series A Preferred Stock | 20,000 | 0.00 | — | 0 | — | ↗ |
| 2019-07-29 | CONRAD HERBERT J | Director | C-Conversion | A | Series A Preferred Stock | 20,000 | 0.00 | — | 0 | — | ↗ |
| 2019-07-26 | STERN ADAM K | Director | C-Conversion | A | Common Stock, par value $0.0001 per share | 200,000 | 0.00 | — | 993,992 | — | ↗ |
| 2019-07-26 | CONRAD HERBERT J | Director | J-Other | A | Common Stock, par value $0.0001 per share | 48,000 | 0.00 | — | 445,983 | — | ↗ |
| 2019-06-30 | WIKLER MATTHEW | Director | A-Award | A | Common Stock | 18,524 | 0.00 | — | 129,745 | — | ↗ |
| 2019-06-30 | Scibetta James S | Director | A-Award | A | Common Stock | 21,879 | 0.00 | — | 577,159 | — | ↗ |
| 2019-06-30 | CONRAD HERBERT J | Director | A-Award | A | Common Stock, par value $0.0001 per share | 28,005 | 0.00 | — | 197,983 | — | ↗ |
| 2019-06-21 | WIKLER MATTHEW | Director | J-Other | A | Common Stock, par value $0.0001 per share | 1,200 | 0.00 | — | 156,124 | — | ↗ |
| 2019-06-21 | Scibetta James S | Director | J-Other | A | Common Stock, par value $0.0001 per share | 2,400 | 0.00 | — | 609,298 | — | ↗ |
| 2019-06-21 | STERN ADAM K | Director | J-Other | A | Common Stock, par value $0.0001 per share | 17,000 | 0.00 | — | 3,256,483 | — | ↗ |
| 2019-06-21 | MANNINO RAPHAEL J | Officer | J-Other | A | Common Stock, par value $0.0001 per share | 2,000 | 0.00 | — | 1,426,565 | — | ↗ |
| 2019-06-21 | Jabbour Jerome D | Director / Officer | J-Other | A | Common Stock, par value $0.0001 per share | 3,000 | 0.00 | — | 789,511 | — | ↗ |
| 2019-06-21 | Ende Eric J | Director | J-Other | A | Common Stock, par value $0.0001 per share | 2,400 | 0.00 | — | 111,692 | — | ↗ |
| 2019-06-21 | CONRAD HERBERT J | Director | J-Other | A | Common Stock, par value $0.0001 per share | 20,000 | 0.00 | — | 465,983 | — | ↗ |
| 2019-06-14 | STERN ADAM K | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 15,000 | 0.80 | 12.0K | 3,239,483 | — | ↗ |
| 2019-06-12 | STERN ADAM K | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 20,000 | 0.80 | 16.0K | 3,224,483 | — | ↗ |
| 2019-06-12 | Jabbour Jerome D | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 12,487 | 0.80 | 10.0K | 771,861 | — | ↗ |
| 2019-06-10 | STERN ADAM K | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 15,000 | 0.82 | 12.3K | 3,204,483 | — | ↗ |
| 2019-06-07 | STERN ADAM K | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 20,000 | 0.89 | 17.8K | 3,189,483 | — | ↗ |
| 2019-05-31 | STERN ADAM K | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 80,000 | 0.94 | 75.2K | 3,169,483 | — | ↗ |
| 2019-05-16 | STERN ADAM K | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 150,000 | 0.95 | 142.5K | 3,089,483 | — | ↗ |
| 2019-05-16 | LEPORE PATRICK G | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 100,000 | 0.95 | 95.3K | 100,000 | — | ↗ |
| 2019-05-16 | CONRAD HERBERT J | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 25,000 | 0.96 | 24.1K | 172,959 | — | ↗ |
| 2019-03-31 | WIKLER MATTHEW | Director | A-Award | A | Common Stock | 14,565 | 0.00 | — | 111,221 | — | ↗ |
| 2019-03-31 | Scibetta James S | Director | A-Award | A | Common Stock | 17,202 | 0.00 | — | 555,280 | — | ↗ |
| 2019-03-31 | CONRAD HERBERT J | Director | A-Award | A | Common Stock | 22,019 | 0.00 | — | 122,019 | — | ↗ |
| 2019-03-19 | STERN ADAM K | Director | W-Will | A | Common Stock, par value $0.0001 per share | 6,600 | 0.00 | — | 1,058,992 | — | ↗ |
| 2019-02-25 | Ferguson James J. III | Officer | A-Award | A | Stock option (right to buy) | 350,000 | 1.09 | 381.5K | 350,000 | — | ↗ |
| 2019-02-11 | Matkovits Theresa | Officer | A-Award | A | Option (right to buy) | 350,000 | 1.08 | 378.0K | 350,000 | — | ↗ |
| 2019-02-11 | MANNINO RAPHAEL J | Officer | A-Award | A | Stock option (right to buy) | 150,000 | 1.08 | 162.0K | 150,000 | — | ↗ |
| 2019-02-11 | Kucinski Keith A | Officer | A-Award | A | Stock option (right to buy) | 275,000 | 1.08 | 297.0K | 275,000 | — | ↗ |
| 2019-02-11 | Jabbour Jerome D | Director / Officer | A-Award | A | Stock option (right to buy) | 750,000 | 1.08 | 810.0K | 750,000 | — | ↗ |
| 2019-02-08 | CONRAD HERBERT J | Director | G-Gift | D | Common Stock | 3,932,903 | 0.00 | — | 100,000 | — | ↗ |
| 2019-01-02 | Kucinski Keith A | Officer | A-Award | A | Stock option (right to buy) | 250,000 | 0.61 | 152.5K | 250,000 | — | ↗ |
| 2018-12-31 | WIKLER MATTHEW | Director | A-Award | A | Common Stock | 26,681 | 0.00 | — | 96,656 | — | ↗ |
| 2018-12-31 | Scibetta James S | Director | A-Award | A | Common Stock | 31,513 | 0.00 | — | 538,078 | — | ↗ |
| 2018-12-31 | Ende Eric J | Director | A-Award | A | Common Stock | 15,022 | 0.00 | — | 57,091 | — | ↗ |
| 2018-12-31 | CONRAD HERBERT J | Director | A-Award | A | Common Stock | 40,337 | 0.00 | — | 4,032,903 | — | ↗ |
| 2018-11-01 | WIKLER MATTHEW | Director | A-Award | A | Stock option (right to buy) | 128,299 | 0.74 | 94.9K | 128,299 | — | ↗ |
| 2018-11-01 | Scibetta James S | Director | A-Award | A | Stock option (right to buy) | 128,299 | 0.74 | 94.9K | 128,299 | — | ↗ |
| 2018-11-01 | STERN ADAM K | Director | A-Award | A | Stock option (right to buy) | 128,299 | 0.74 | 94.9K | 128,299 | — | ↗ |
| 2018-11-01 | LEPORE PATRICK G | Director | A-Award | A | Stock option (right to buy) | 128,299 | 0.74 | 94.9K | 128,299 | — | ↗ |
| 2018-11-01 | Ende Eric J | Director | A-Award | A | Stock option (right to buy) | 128,299 | 0.74 | 94.9K | 128,299 | — | ↗ |
| 2018-11-01 | CONRAD HERBERT J | Director | A-Award | A | Stock option (right to buy) | 128,299 | 0.74 | 94.9K | 128,299 | — | ↗ |
| 2018-10-15 | Matkovits Theresa | Officer | A-Award | A | Option (right to buy) | 350,000 | 0.79 | 276.5K | 350,000 | — | ↗ |
| 2018-10-01 | WIKLER MATTHEW | Director | A-Award | A | Common Stock | 19,294 | 0.00 | — | 69,975 | — | ↗ |
| 2018-10-01 | Scibetta James S | Director | A-Award | A | Common Stock | 20,381 | 0.00 | — | 506,565 | — | ↗ |
| 2018-10-01 | Ende Eric J | Director | A-Award | A | Common Stock | 9,715 | 0.00 | — | 42,069 | — | ↗ |
| 2018-10-01 | CONRAD HERBERT J | Director | A-Award | A | Common Stock | 26,087 | 0.00 | — | 3,992,566 | — | ↗ |
| 2018-09-05 | LEPORE PATRICK G | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-06-29 | WIKLER MATTHEW | Director | A-Award | A | Common Stock | 32,259 | 0.00 | — | 50,681 | — | ↗ |
| 2018-06-29 | Scibetta James S | Director | A-Award | A | Common Stock | 43,203 | 0.00 | — | 486,184 | — | ↗ |
| 2018-06-29 | Ende Eric J | Director | A-Award | A | Common Stock | 20,594 | 0.00 | — | 32,354 | — | ↗ |
| 2018-06-29 | CONRAD HERBERT J | Director | A-Award | A | Common Stock | 55,300 | 0.00 | — | 3,966,479 | — | ↗ |
| 2018-06-21 | WIKLER MATTHEW | Director | P-Purchase | A | Series B Convertible Preferred Stock | 6 | 0.50 | 3.00 | 6 | — | ↗ |
| 2018-06-21 | Scibetta James S | Director | P-Purchase | A | Series B Convertible Preferred Stock | 12 | 0.50 | 6.00 | 12 | — | ↗ |
| 2018-06-21 | STERN ADAM K | Director | P-Purchase | A | Series B Convertible Preferred Stock | 85 | 0.50 | 42.50 | 85 | — | ↗ |
| 2018-06-21 | MANNINO RAPHAEL J | Officer | P-Purchase | A | Series B Convertible Preferred Stock | 10 | 0.50 | 5.00 | 10 | — | ↗ |
| 2018-06-21 | Jabbour Jerome D | Director / Officer | P-Purchase | A | Series B Convertible Preferred Stock | 15 | 0.50 | 7.50 | 15 | — | ↗ |
| 2018-06-21 | Ende Eric J | Director | P-Purchase | A | Series B Convertible Preferred Stock | 12 | 0.50 | 6.00 | 12 | — | ↗ |
| 2018-06-21 | CONRAD HERBERT J | Director | P-Purchase | A | Series B Convertible Preferred Stock | 100 | 0.50 | 50.00 | 100 | — | ↗ |
| 2018-04-30 | WIKLER MATTHEW | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.44 | 44.0K | 100,000 | — | ↗ |
| 2018-04-30 | MANNINO RAPHAEL J | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 0.44 | 66.0K | 150,000 | — | ↗ |
| 2018-04-30 | Gaglione Gary | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-04-30 | DiPaolo Dominick | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 0.44 | 66.0K | 150,000 | — | ↗ |
| 2018-03-30 | WIKLER MATTHEW | Director | A-Award | A | Common Stock | 18,422 | 0.00 | — | 18,422 | — | ↗ |
| 2018-03-30 | Scibetta James S | Director | A-Award | A | Common Stock | 24,672 | 0.00 | — | 442,981 | — | ↗ |
| 2018-03-30 | Ende Eric J | Director | A-Award | A | Common Stock | 11,760 | 0.00 | — | 11,760 | — | ↗ |
| 2018-03-30 | CONRAD HERBERT J | Director | A-Award | A | Common Stock | 31,579 | 0.00 | — | 3,911,179 | — | ↗ |
Executive team
Top executives
Shares Outstanding
5.55M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Jerome D. Jabbour Chief Executive Officer | 598.0K | — | — | — | — | — | 598.0K | 0.00% | ↗ |
| 2 | 2024 | James J. Ferguson Former Chief Medical Officer | 468.0K | 121.7K | — | — | — | — | 589.7K | 0.00% | ↗ |
| 3 | 2024 | Keith Kucinski Chief Financial Officer | 416.0K | 168.2K | — | — | — | — | 584.2K | 0.00% | ↗ |
| 4 | 2023 | Jerome D. Jabbour Chief Executive Officer | 598.0K | 244.4K | — | 757.2K | — | — | 1.60M | 47.34% | ↗ |
| 5 | 2023 | James J. Ferguson Former Chief Medical Officer | 468.0K | 153.0K | — | 259.6K | — | — | 880.6K | 29.48% | ↗ |
| 6 | 2023 | Keith Kucinski Chief Financial Officer | 416.0K | 176.0K | — | 216.3K | — | — | 808.3K | 26.76% | ↗ |
| 7 | 2022 | Jerome D. Jabbour Chief Executive Officer | 575.0K | 306.5K | — | 792.7K | — | — | 1.67M | 47.35% | ↗ |
| 8 | 2022 | James J. Ferguson Chief Medical Officer | 450.0K | 169.9K | — | 249.2K | — | — | 869.1K | 28.67% | ↗ |
| 9 | 2022 | Theresa Matkovits Chief Development Officer | 412.0K | 189.0K | — | 249.2K | — | — | 850.2K | 29.31% | ↗ |
| 10 | 2021 | Jerome D. Jabbour Chief Executive Officer | 545.0K | 250.0K | — | 2.90M | — | — | 3.69M | 78.47% | ↗ |
| 11 | 2021 | James J. Ferguson Chief Medical Officer | 422.3K | 164.0K | — | 1.04M | — | — | 1.62M | 63.85% | ↗ |
| 12 | 2021 | Theresa Matkovits Chief Development Officer | 378.5K | 147.0K | — | 812.6K | — | — | 1.34M | 60.73% | ↗ |
| 13 | 2020 | Jerome D. Jabbour Chief Executive Officer | 500.0K | 250.0K | — | 2.18M | — | — | 2.93M | 74.40% | ↗ |
| 14 | 2020 | James J. Ferguson Chief Medical Officer | 410.0K | 150.0K | — | 1.09M | — | — | 1.65M | 66.06% | ↗ |
| 15 | 2020 | Theresa Matkovits Chief Development Officer | 367.5K | 122.5K | — | 763.0K | — | — | 1.25M | 60.89% | ↗ |
| 16 | 2019 | Jerome D. Jabbour Chief Executive Officer | 444.8K | 200.0K | — | 680.4K | — | — | 1.33M | 51.34% | ↗ |
| 17 | 2019 | James J. Ferguson Chief Medical Officer | 319.4K | 50.0K | — | 319.9K | — | 62.9K | 752.3K | 42.53% | ↗ |
| 18 | 2019 | Theresa Matkovits Chief Development Officer | 350.0K | 30.6K | — | 317.5K | — | — | 698.1K | 45.48% | ↗ |
| 19 | 2019 | Keith A. Kucinski Chief Financial Officer | 249.1K | — | — | 377.5K | — | — | 626.6K | 60.25% | ↗ |
| 20 | 2019 | Roelof Rongen Former Chief Executive Officer | — | — | — | — | — | 183.3K | 183.3K | 0.00% | ↗ |
| 21 | 2018 | Jerome D. Jabbour Chief Executive Officer | 366.5K | 84.0K | — | 804.3K | — | — | 1.25M | 64.10% | ↗ |
| 22 | 2018 | Roelof Rongen Former Chief Executive Officer | 183.3K | — | — | — | — | 216.7K | 400.0K | 0.00% | ↗ |
| 23 | 2018 | Theresa Matkovits Chief Development Officer | 74.3K | — | — | 232.0K | — | — | 306.3K | 75.75% | ↗ |
| 24 | 2018 | Raphael Mannino Chief Scientific Officer | 240.0K | — | — | 54.6K | — | — | 294.6K | 18.54% | ↗ |
| 25 | 2018 | Gary Gaglione Former Chief Financial Officer | 165.0K | — | — | 77.6K | — | — | 242.6K | 31.99% | ↗ |
| 26 | 2018 | Keith A. Kucinski Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 27 | 2018 | James J. Ferguson Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 28 | 2017 | Roelof Rongen Former Chief Executive Officer | 383.3K | 160.0K | — | 1.32M | — | — | 1.87M | 70.88% | ↗ |
| 29 | 2017 | Roelof Rongen Former Chief Executive Officer | 383.3K | 160.0K | — | 1.32M | — | — | 1.87M | 70.88% | ↗ |
| 30 | 2017 | Jerome D. Jabbour Chief Executive Officer | 299.0K | 90.0K | — | 881.5K | — | — | 1.27M | 69.38% | ↗ |
| 31 | 2017 | Jerome D. Jabbour, Chief Executive Officer and President | 299.0K | 90.0K | — | 881.5K | — | — | 1.27M | 69.38% | ↗ |
| 32 | 2017 | Dominick DiPaolo Former Senior Vice President, Quality and Regulatory Compliance | 188.1K | — | — | 960.8K | — | — | 1.15M | 83.62% | ↗ |
| 33 | 2017 | Raphael Mannino Chief Scientific Officer | 238.3K | 70.0K | — | 275.5K | — | — | 583.8K | 47.18% | ↗ |
| 34 | 2017 | Gary Gaglione Former Chief Financial Officer | 218.3K | 50.0K | — | 275.5K | — | — | 543.8K | 50.66% | ↗ |
| 35 | 2016 | Roelof Rongen Former Chief Executive Officer | 283.8K | 160.0K | — | 116.3K | — | — | 560.0K | 20.76% | ↗ |
| 36 | 2016 | Roelof Rongen Chief Executive Officer | 283.8K | 160.0K | — | 116.3K | — | — | 560.0K | 20.76% | ↗ |
| 37 | 2016 | Jerome D. Jabbour, Chief Executive Officer and President | 282.8K | 90.0K | — | 108.5K | — | — | 481.3K | 22.54% | ↗ |
| 38 | 2016 | Jerome D. Jabbour, President | 282.8K | 90.0K | — | 108.5K | — | — | 481.3K | 22.54% | ↗ |
| 39 | 2016 | Douglas F. Kling Senior Vice President, Clinical Development Project Management | 236.5K | 100.0K | — | 62.0K | — | — | 398.5K | 15.56% | ↗ |
| 40 | 2016 | Dominick DiPaolo Former Senior Vice President, Quality and Regulatory Compliance | — | — | — | — | — | — | — | — | ↗ |
| 41 | 2015 | Roelof Rongen Chief Executive Officer | 300.0K | 132.0K | — | 101.6K | — | — | 533.6K | 19.05% | ↗ |
| 42 | 2015 | Jerome D. Jabbour, President | 293.0K | 90.8K | — | — | — | — | 443.0K | 0.00% | ↗ |
| 43 | 2015 | Douglas F. Kling Senior Vice President, Clinical Development Project Management | 198.8K | — | — | 145.6K | — | — | 344.4K | 42.27% | ↗ |
| 44 | 2015 | Abdel A. Fawzy Executive Vice President, Supply Chain Development | 250.0K | 60.0K | — | 33.9K | — | — | 343.9K | 9.85% | ↗ |
| 45 | 2014 | Roelof Rongen Chief Executive Officer | 300.0K | 50.0K | — | 268.8K | — | — | 618.8K | 43.44% | ↗ |
| 46 | 2014 | Jerome D. Jabbour, President | 275.0K | 30.0K | — | — | — | — | 573.8K | 0.00% | ↗ |
| 47 | 2014 | Abdel A. Fawzy Executive Vice President, Supply Chain Development | 250.0K | 25.0K | — | 268.8K | — | — | 543.8K | 49.43% | ↗ |
| 48 | 2014 | Roelof Rongen President and Chief Executive Officer | 300.0K | 50.0K | — | 112.0K | — | — | 462.0K | 24.24% | ↗ |
| 49 | 2014 | Jerome D. Jabbour, Executive Vice President, Chief Business Officer, General Counsel and Secretary | 275.0K | 30.0K | — | 112.0K | — | — | 417.0K | 26.86% | ↗ |
| 50 | 2014 | George Bobotas Executive Vice President and Chief Scientific Officer | 250.0K | 25.0K | — | 112.0K | — | — | 387.0K | 28.94% | ↗ |
| 51 | 2013 | Roelof Rongen President and Chief Executive Officer | 27.3K | 150.0K | — | 32.0K | — | 1.9K | 311.2K | 10.27% | ↗ |
| 52 | 2013 | George Bobotas Executive Vice President and Chief Scientific Officer | 106.1K | 125.0K | — | 32.0K | — | — | 263.1K | 12.15% | ↗ |
| 53 | 2013 | Abdel A. Fawzy Executive Vice President, Supply Chain Development | 106.1K | 125.0K | — | 32.0K | — | — | 263.1K | 12.15% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jerome D. Jabbour | Co-Founder, Chairman, CEO, President & Interim CFO | 598.0K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MTNB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
